New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2013
14:13 EDTACT, TEVAActavis wins part of appeals court ruling against Teva unit
A U.S. appeals court reversed part of a ruling in favor of Watson Pharmaceuticals, now known as Actavis (ACT), over Teva's (TEVA) Cephalon unit in a patent lawsuit over the cancer drug Fendora. The appeals court upheld a lower court's ruling that a generic version made by Actavis did not copy the way the drug is delivered into the system through a mucous membrane. The appeals court did overturn a lower court ruling that the patents are invalid, however.Reference Link
News For ACT;TEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 31, 2014
16:18 EDTACTActavis, Durata announce FTC grants early termination of HSR Act
Actavis (ACT) and Durata Therapeutics (DRTX) announced that the FTC has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to Actavis' pending acquisition of Durata. The early termination of the HSR waiting period satisfies one of the conditions to the closing of the pending acquisition, which remains subject to other customary closing conditions. Both companies expect the transaction to be completed in Q4.
October 30, 2014
09:39 EDTACTPerrigo in exclusive talks to buy Omega Pharma, Bloomberg says
Subscribe for More Information
09:18 EDTACTPerrigo in exclusive talks to buy Omega Pharma, Bloomberg says
Subscribe for More Information
09:11 EDTTEVATeva reported great Q3 results, says BMO Capital
Subscribe for More Information
09:06 EDTTEVATeva says assessing M&A opportunities of all sizes
08:49 EDTTEVATeva says may pursue generic businesses in emerging markets
Says not ruling out "transformational" transactions. Says open to specialty assets in U.S., Europe.
08:40 EDTTEVATeva says $5.00-$5.10 FY14 EPS guidance is for exclusive Copaxone scenario
Subscribe for More Information
07:06 EDTTEVATeva board authorizes increase in share repurchase program to $3B
The Company announced today that, as authorized by the Board of Directors, it will increase its share repurchase program by $1.7 billion to $3 billion. The program has no time limitations. The Company intends to begin purchasing shares promptly.
07:05 EDTTEVATeva raises FY14 EPS view to $5.00-$5.10 from $4.90-$5.10
Subscribe for More Information
07:05 EDTTEVATeva reports Q3 EPS $1.32, consensus $1.23
Subscribe for More Information
October 27, 2014
15:18 EDTACTEarnings Preview: Pfizer looks to new products to offset generic competition
Subscribe for More Information
10:36 EDTACTAllergan delivers earnings beat, says willing to consider higher Valeant bid
Subscribe for More Information
07:22 EDTTEVAAmerican College of Chest Physicians to hold a conference
Subscribe for More Information
October 23, 2014
18:18 EDTACTGlenview Capital acquires stake in Actavis, Bloomberg reports
Subscribe for More Information
08:10 EDTACTActavis confirms appeals court upholds Lo Loestrin Fe patent
Subscribe for More Information
October 22, 2014
08:38 EDTACTActavis signs option to acquire Rhythm Health
Subscribe for More Information
October 21, 2014
06:44 EDTACTActavis among bidders for Omega Pharma, Bloomberg reports
Subscribe for More Information
October 20, 2014
18:51 EDTACTOn The Fly: After Hours Movers
Subscribe for More Information
06:28 EDTTEVA, ACTAllergan price target raised to $210 from $190 at Citigroup
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use